NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
28 trialsNCT04388384 2025-08-06
ELEANOR
Pierre Fabre Pharma GmbH
Completed
NCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT06083662 2025-03-18
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
Phase 2 Completed
NCT04366713 2023-02-10
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Puma Biotechnology, Inc.
Phase 2 Completed
NCT02236000 2023-01-26
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NSABP Foundation Inc
Phase 1/2 Completed
NCT01670877 2022-04-15
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT01008150 2021-10-25
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT00878709 2021-06-11
ExteNET
Puma Biotechnology, Inc.
Phase 3 Completed
NCT01808573 2021-06-11
NALA
Puma Biotechnology, Inc.
Phase 3 Completed
NCT01128842 2018-12-19
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00768469 2018-11-19
Study Evaluating Safety And Tolerability, Solid Tumor
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00838539 2018-09-18
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00146172 2018-09-17
Study Evaluating HKI-272 in Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00397046 2018-09-14
A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00741260 2018-09-05
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00915018 2018-08-22
NEFERTT
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00300781 2018-08-14
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00706030 2018-08-09
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00445458 2018-07-26
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT00398567 2018-07-24
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 1/2 Completed
NCT01827267 2018-07-03
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00958724 2018-06-28
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT00266877 2018-04-13
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00366600 2017-09-11
Study Evaluating HKI-272 Administered to Healthy Subjects
Puma Biotechnology, Inc.
Phase 1 Completed
NCT01423123 2014-07-08
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
NSABP Foundation Inc
Phase 1 Completed
NCT00708903 2012-05-14
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
Puma Biotechnology, Inc.
Phase 1 Completed